Anti-diabetic complications

alpha-Amyrin
Catalog No: CFN92377

Alpha-Amyrin is trypsin and chymotrypsin inhibitor,it has antineoplastic,it induces proliferation of human keratinocytes.Alpha-Amyrin can as a hepatomodulatory potent to feasibility for a promising liver curative drug.

Nothofagin
Catalog No: CFN92888

Nothofagin has antioxidant, and antithrombotic activities, it possesses anti-inflammatory activity by inhibiting hyperpermeability, expression of CAMs, and adhesion and migration of leukocytes, thereby endorsing its usefulness as a therapy for vascular inflammatory diseases. Nothofagin may have significant benefits in the treatment of diabetic complications. Nothofagin has potential to as an anti-sendothelial cell protein C receptor shedding reagent against phorbol-12-myristate 13-acetate and cecal ligation and puncture -mediated endothelial cell protein C receptor shedding.

Alliin
Catalog No: CFN93533

Alliin has antiglycating potential , it offers protection against glucose or methyglyoxal induced glycation of superoxide dismutase, hence is expected to have therapeutic potential in the prevention of glycation-mediated diabetic complications. Alliin has anti-inflammatory activity, it protects against Lipopolysaccharides (LPS)-induced acute lung injury (ALI) by activating PPARγ, which subsequently inhibits LPS-induced NF-κB activation and inflammatory response; alliin has an inhibitory effect in osteoclasteogenesis with a dose-dependent manner via blocking the c-Fos-NFATc1 signaling pathway, it could be a potential therapeutic agent in the treatment of osteoporosis. Alliin and sabinene have detectable levels of antimicrobial activity.

Rubrofusarin-6-O-beta-D-gentiobioside
Catalog No: CFN90827

Rubrofusarin-6-O-beta-D-gentiobioside can significantly decrease the expression of TGF-beta1 and fibronectin and NF-kappaB DNA binding activity, suggests that it has potential as a preventive agent for advanced glycation end products-related diabetic complications.

Marein
Catalog No: CFN90851

Marein shows neuroprotective effect on PC12 cell damage induced by methylglyoxal, which is due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway, it may be a potent compound for preventing/counteracting diabetic encephalopathy. Marein can improve insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein shows antioxidant activity, it shows Histone deacetylase enzymes (HDACs) inhibitory activity and it also can inhibit TNFα-induced NF-κB activation.